Analysts Anticipate Kodiak Sciences Inc. (NASDAQ:KOD) to Post -$1.61 EPS

Wall Street brokerages expect Kodiak Sciences Inc. (NASDAQ:KODGet Rating) to post ($1.61) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kodiak Sciences’ earnings, with estimates ranging from ($1.97) to ($0.81). Kodiak Sciences reported earnings per share of ($1.08) in the same quarter last year, which suggests a negative year over year growth rate of 49.1%. The business is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Kodiak Sciences will report full year earnings of ($6.64) per share for the current fiscal year, with EPS estimates ranging from ($8.52) to ($3.30). For the next year, analysts expect that the firm will post earnings of ($4.92) per share, with EPS estimates ranging from ($7.74) to ($2.93). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Kodiak Sciences.

Kodiak Sciences (NASDAQ:KODGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.51) by ($0.32). During the same quarter in the previous year, the company earned ($0.98) EPS.

A number of equities research analysts have recently weighed in on KOD shares. Citigroup cut their price objective on Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 24th. Barclays dropped their price target on Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating on the stock in a research report on Monday, February 7th. Truist Financial cut their target price on Kodiak Sciences from $147.00 to $35.00 in a research note on Thursday, February 24th. Roth Capital dropped their price target on shares of Kodiak Sciences from $149.00 to $75.00 in a research note on Monday, February 28th. Finally, The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research note on Friday, February 11th. They set a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Kodiak Sciences presently has an average rating of “Hold” and a consensus target price of $45.33.

Shares of NASDAQ KOD traded up $1.19 during midday trading on Tuesday, reaching $9.03. The company had a trading volume of 69,641 shares, compared to its average volume of 1,054,977. The stock has a market cap of $469.11 million, a PE ratio of -1.51 and a beta of 1.97. Kodiak Sciences has a one year low of $4.90 and a one year high of $26.39. The firm’s fifty day moving average price is $6.70 and its 200-day moving average price is $39.15.

In other news, Director Bros. Advisors Lp Baker purchased 223,766 shares of the stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $5.97 per share, with a total value of $1,335,883.02. Following the acquisition, the director now directly owns 15,142,074 shares of the company’s stock, valued at $90,398,181.78. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have purchased 816,015 shares of company stock worth $5,670,730. 39.70% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock worth $26,526,000 after purchasing an additional 584,762 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Kodiak Sciences in the 1st quarter worth approximately $3,603,000. Krensavage Asset Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth approximately $3,479,000. Walleye Capital LLC grew its position in Kodiak Sciences by 1,904.5% during the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock valued at $2,749,000 after buying an additional 338,328 shares during the period. Finally, Graham Capital Management L.P. purchased a new stake in Kodiak Sciences during the first quarter valued at approximately $2,282,000. Institutional investors own 69.80% of the company’s stock.

About Kodiak Sciences (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Read More

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with's FREE daily email newsletter.